Therapeutic Application of Botulinum Neurotoxin in Pain: A pre-clinical approach
Mikhail Kalinichev, Director of In Vivo Neurology at Ipsen will be joining SMi’s Pain Therapeutics Conference speaker panel and cover the topic of Therapeutic Application of Botulinum Neurotoxin in Pain: A pre-clinical approach:
- While the therapeutic application of botulinum neurotoxin in pain field has grown rapidly during the last decades, the growth has been led primarily by observations and studies performed in the clinic
- Testing botulinum neurotoxin in pre-clinical models of pain can provide an opportunity for systematic evaluation of treatment variables and subsequent improvements in clinical study design
- Pre-clinical experiments can also help further our understanding of the mechanisms mediating therapeutic efficacy of neurotoxin in pain and in designing a range of modified neurotoxin molecules with enhanced therapeutic profiles
More speakers from:
Cara Therapeutics, Centrexion Therapeutics, Amgen, Aptinyx, AstraZeneca, Danish Headache Centre, Eli Lilly, Grunenthal
Innopain, Lotus Clinical Research, Novartis, Prescient Healthcare Group and many others!
View more information on featured topics and speaker panel at www.pain-therapeutics.co.uk/pharmajournPR
Pain Therapeutics Conference on Twitter – @SMIpharm and #smipaintherapeutics
————————————————————————————————————-
Pain Therapeutics Conference | 21 – 22 May 2018 | London, UK
————————————————————————————————————-